WILL YOU BE ALLOWED ACCESS TO THE COVID CURES?
“Catching COVID-19 was a blessing from God”
President Donald Trump
The newly accessible COVID-19 treatments are –
- * RONAPREVE, a combination of the monoclonal antibodies casirivimab and imdevimab, is designed to attach to the protein spikes of the SARS-CoV-2 virus preventing the virus particles from penetrating the body’s cells.
Ronapreve is administered by a single intravenous infusion which can be given at home under medical supervision at a cost of $800 (as related by my English patient).
On 2 October 2020, President Trump received “a single 8 gram dose of REGN-COV2”, and, much to our surprise, was tottering back on his feet and speaking a little sense within four days of his admission to the Walter Reed military hospital with a critical blood oxygen level in the 80s.
Ronapreve was developed and is manufactured by Regeneron Pharmaceuticals Inc, largely funded by the US Government under the code name Operation Warp Speed.
The company was founded in 1988 by Leonard Schleifer, formerly Professor of Medicine at Weill Cornell Medical School, and scientist George Yancopoulos of Columbia University, both from Queens, New York.
Between the two of them they hold an estimated $4 billion in Regeneron stock.
Dr Schleifer is a member of President Trump’s golf club in Westchester County, New York.
- * LAGEVRIO, molnupiravir, a potent ribonucleoside analog, being an inactive copy of the RNA of SARS-CoV-2, the causative agent of COVID-19, it strongly inhibits the replication of the virus.
Unlike the specific protein spike focused vaccines, molnupiravir fundamentally cripples all 20,000 coronaviruses – along with the influenza family – and more, it is claimed.
Lagevrio is an oral preparation to be taken as a course of one capsule twice a day for five days at a cost of $700.
Molnupiravir was invented at Emory University, Atlanta, a private research university founded by the Methodist Episcopal Church in 1836, and re-invigorated in 1979 by a gift of $105 million of Coca-Cola stock from the Woodruff brothers.
Molnupiravir was developed by Merck & Co., Inc, MSD, and financed by Merck along with hedge funders Dr Wayne and Mrs Wendy Holman of Ridgeback Biotherapeutics of Miami.
History in the making.
. . .
The UK government has stockpiled 480,000 courses of Lagevrio molnupiravir. Merck will have produced 10 million courses by the end of December: 20 million courses might be produced in 2022.
As of 16 December 2021, these anti-viral medicines are to be supplied through the NHS free of charge to eligible COVID-19 positive patients until 31 March 2022.
The eligibility for free treatment will be strictly limited to the immunocompromised, cancer patients, those suffering from Down’s syndrome, some brain and nerve diseases and HIV or AIDS.*
It remains to be seen whether the excluded elderly, the obese, the sufferers from respiratory and cardiovascular diseases, and, indeed, anybody else in the UK, will have access to these truly miraculous treatments.
. . .
*Treatments for coronavirus (COVID-19). NHS. Last reviewed 9 December 2021.